Recent Updates
Recently added Catalysts
CAH Positive Sentiment Score: 85/100

Bob Azelby to join Cardinal Health Board of Directors

Key Takeaway: Cardinal Health announced the election of Robert 'Bob' Azelby as an independent director on its Board of Directors, effective March 1, 2024. Azelby has over 30 years of experience in the healthcare industry, holding leadership positions at various biopharmaceutical organizations. His extensive background in oncology and specialty pharmaceuticals is expected to provide significant value to the company as it pursues its strategic priorities. The board's chairman highlighted Azelby's strong track record, indicating confidence in his ability to contribute meaningfully to the company's future.

Market Sentiment Analysis

POSITIVE FACTORS

  • Bob Azelby brings over 30 years of experience in the biopharmaceutical sector.
  • His past leadership roles at major companies like Eliem and Alder BioPharmaceuticals enhance Cardinal Health's board.
  • The appointment is viewed as a strategic move to drive momentum in specialty pharmaceuticals.

Full Press Release Details

EX-99.1 2 exhibit991-feb2024newbodme.htm EX-99.1 Document Exhibit 99.1 Bob Azelby to join Cardinal Health Board of Directors DUBLIN, Ohio, February 28, 2024 - Cardinal Health (NYSE CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby has previously served as President and Chief Executive Officer of Eliem Therapeutics, and prior to Eliem, he was the Chief Executive Officer of Alder BioPharmaceuticals. Before joining Alder BioPharmaceuticals, Mr. Azelby was the Chief Commercial Officer of Juno Therapeutics, and served 15 years in a variety of commercial roles at Amgen. Mr. Azelby currently serves on the Boards of Directors of ADC Therapeutics and Autolus Therapeutics. He also formerly served on the Boards of Directors for Chinook Therapeutics, Eliem Therapeutics, Clovis Oncology, Immunomedics, Alder BioPharmaceuticals, and Cascadian Therapeutics. "Bob Azelby is a highly respected healthcare industry leader with a strong track record of leading large, complex organizations as both a CEO and a board member," said Greg Kenny, Chairman of the Board for Cardinal Health. "Bob's vast experience and expertise within the specialty pharmaceutical arena will add great value to our company and we're pleased to welcome him to our board." "Bob brings to our board more than three decades of experience and high performance across a multitude of healthcare industries, including oncology and other specialty areas, which I believe will make him a uniquely valuable addition," said Jason Hollar, CEO of Cardinal Health. "We look forward to tapping into Bob's extensive expertise as we continue the momentum against our strategic priorities." Mr. Azelby holds a BA in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With more than 50 years in business, operations in more than 30 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com. Contacts Media Erich Timmerman, erich.timmerman cardinalhealth.com and 614.757.8231 Investors Matt Sims, matt.sims cardinalhealth.com and 614.553.3661

Frequently Asked Questions

Who is the new member of Cardinal Health's Board of Directors?

Robert 'Bob' Azelby has been elected as an independent director.

When will Bob Azelby officially join the board?

He will officially join the Board on March 1, 2024.

What is Bob Azelby's professional background?

He has over 30 years of experience in biopharmaceutical and specialty industries.

What companies has Bob Azelby previously worked for?

He has worked at Eliem Therapeutics, Alder BioPharmaceuticals, and Amgen.

What degrees does Bob Azelby hold?

He holds a BA in Economics and an MBA from Harvard Business School.

Last updated: Feb 28, 2024